Research on Long-Term Bisphosphonate Use and Osteoporotic Fractures

Understanding Osteoporosis and Its Risks

Osteoporosis significantly increases the likelihood of fractures due to diminished bone mineral density. It is estimated that approximately 50% of women over the age of 50 will suffer from an osteoporotic fracture.

The Role of Bisphosphonates

Bisphosphonates, a class of medications that inhibit bone tissue breakdown and remodeling, are the most prevalent treatment prescribed for osteoporosis. However, existing review studies have not established definitive evidence that long-term use of bisphosphonates effectively prevents fractures in women diagnosed with osteoporosis.

FDA Recommendations

The Food and Drug Administration (FDA) advises individuals on bisphosphonate therapy to undergo periodic evaluations. This recommendation stems from findings in smaller-scale studies that raised concerns regarding the long-term safety of these medications.

Large-Scale Analysis from the Women’s Health Initiative

To address the need for more extensive analysis, a team of American researchers conducted a retrospective examination of data from the Women’s Health Initiative (WHI), a comprehensive long-term study focused on women’s health that began in 1993. The WHI encompasses both clinical trials and observational studies that investigate the effects of hormonal and dietary interventions on conditions such as heart disease, cancer, and fractures in postmenopausal women.

Study Methodology

The researchers published their findings in the Journal of the American Geriatric Society. They analyzed data concerning the annual incidence of fractures among women who had reported a minimum of two years of bisphosphonate usage. The study included 5,120 women, with an average follow-up period of 3.7 years. Statistical analyses were performed to assess the relationship between fracture rates and bisphosphonate use, adjusting for variables such as age, physical activity, and overall health.

Key Findings

The study revealed that older women who had taken bisphosphonates for 10 to 13 years experienced higher rates of clinical fractures compared to those who had only used the medication for two years. Conversely, women who had used bisphosphonates for periods of 3 to 5 years and 6 to 9 years did not show a significant association with fracture risk.

The authors speculated that the inhibition of bone tissue breakdown caused by bisphosphonates might lead to long-term structural changes, increasing the likelihood of fractures. Specifically, the suppression of the remodeling process for damaged bones could contribute to their brittleness.

Study Limitations and Next Steps

One notable limitation of the study is the reliance on self-reported data regarding bisphosphonate usage. While the accuracy of this data was supported by prior validity studies, which indicated a strong correlation with clinical or pharmacy records, some fractures were not confirmed through medical records.

These findings prompt concerns regarding the safety of prolonged bisphosphonate therapy and suggest a need to reassess the clinical guidelines that endorse up to 10 years of treatment. Further research is essential to establish optimal guidelines for bisphosphonate use in preventing osteoporotic fractures.

Conclusion

The study emphasizes the importance of continually evaluating treatment protocols for osteoporosis to ensure patient safety and effective fracture prevention.

Author Information

Written by Agustin Dominguez Iino, BSc.

Related Topics of Interest

– What is osteoporosis and how is it treated?
– Treating Osteoporosis with Omega-3 Fatty Acids and Estrogen
– Can We Predict the Risk of Fractures in Women with Postmenopausal Osteoporosis?
– Top drug-based osteoporosis treatment options
– Treating Osteoporosis in Men
– Osteoporotic Fracture and Bisphosphonates: What are the Long-Term Risks?
– Exploring the Impact of Carotenoids on Osteoporotic Fractures

Reference

Drieling RL et al. Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women’s Health Initiative. J Am Geriatr Soc. 2017 Sep;65(9):1924-1931. doi: 10.1111/jgs.14911. Epub 2017 May 29.